Smalls

Small Pharma is a neuropharmaceutical company focused on the development of short-acting psychedelic medicines for the treatment of mental health conditions. The company is a pioneer in the clinical development of N,N-dimethyltryptamine (DMT) and its derivatives, aiming to provide rapid-acting and effective therapies for major depressive disorder and other psychiatric indications. Their lead program, SPL026, has demonstrated promising results in Phase 2a trials, showing significant antidepressant effects with a short treatment duration. In August 2023, Small Pharma was acquired by Cybin, a leading clinical-stage biopharmaceutical company, to create a combined entity with a robust pipeline of next-generation psychedelic candidates.